Jilin Aodong Pharmaceutical Group Co., Ltd. (SHE: 000623)

Jilin Aodong Pharmaceutical Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	2,028	1,720	1,438	1,743	2,504	2,193
Short-Term Investments	-	-	788	704	709	1,490
Trading Asset Securities	1,232	1,658	1,640	2,189	1,300	906.32
Cash & Short-Term Investments	3,259	3,378	3,866	4,635	4,513	4,589
Cash Growth	-11.40%	-12.62%	-16.59%	2.71%	-1.66%	15.89%
Accounts Receivable	1,261	1,407	1,056	964.31	951.03	1,032
Other Receivables	525.95	29.98	60.31	68.53	83.35	110.26
Receivables	1,787	1,437	1,116	1,033	1,034	1,142
Inventory	972.31	872.35	874.57	591.88	548.45	543.59
Prepaid Expenses	-	-	-	0.16	0.01	0.02
Other Current Assets	96.29	57.55	124.69	65.59	87.41	73.67
Total Current Assets	6,115	5,745	5,982	6,326	6,183	6,348
Property, Plant & Equipment	2,580	2,534	2,339	2,296	2,246	2,212
Long-Term Investments	23,634	23,003	21,891	19,637	18,283	16,669
Other Intangible Assets	457.98	435.35	365.08	359.61	329.44	311.34
Long-Term Deferred Tax Assets	393.45	309.84	303.12	164.27	118.52	103.88
Long-Term Deferred Charges	140.67	163.96	212.25	188.02	126.37	94.55
Other Long-Term Assets	102.92	75.77	89.83	96.53	67.6	62.05
Total Assets	33,424	32,266	31,182	29,067	27,353	25,801
Accounts Payable	443.4	418.59	450.97	238.22	262.56	216.79
Accrued Expenses	43.82	148.94	183.15	111.71	107.5	115.79
Short-Term Debt	1,119	678.31	651.27	355.52	373.38	87.24
Current Portion of Long-Term Debt	-	2,315	-	-	-	-
Current Portion of Leases	20.96	17.88	18.23	25.41	-	-
Current Income Taxes Payable	7.76	28.28	11.52	19.31	9.21	18.34
Current Unearned Revenue	28.9	26.26	82.25	18.36	19.95	-
Other Current Liabilities	1,856	834.8	817.97	687.19	611.45	587.51
Total Current Liabilities	3,520	4,468	2,215	1,456	1,384	1,026
Long-Term Debt	994.23	-	2,303	2,211	2,108	2,006
Long-Term Leases	21.82	21.49	17.55	23.38	-	-
Long-Term Unearned Revenue	234.84	247.38	281.6	313.86	321.31	315.95
Long-Term Deferred Tax Liabilities	29.38	30.03	26.06	24.21	9.9	7.38
Other Long-Term Liabilities	-	-	-	-	0.5	0.93
Total Liabilities	4,800	4,767	4,844	4,029	3,824	3,356
Common Stock	1,196	1,168	1,163	1,163	1,163	1,163
Additional Paid-In Capital	4,851	4,035	3,947	3,980	3,965	3,966
Retained Earnings	21,691	21,871	20,741	19,243	17,690	16,213
Treasury Stock	-	-720.07	-570.07	-400.03	-300.03	-
Comprensive Income & Other	617	856.99	753.71	873.11	834.39	907.07
Total Common Equity	28,355	27,212	26,034	24,859	23,353	22,249
Minority Interest	268.67	288.01	303.54	179.26	176.26	195.2
Shareholders' Equity	28,624	27,500	26,338	25,039	23,529	22,445
Total Liabilities & Equity	33,424	32,266	31,182	29,067	27,353	25,801
Total Debt	2,156	3,032	2,990	2,616	2,482	2,094
Net Cash (Debt)	1,103	346.02	875.84	2,020	2,031	2,496
Net Cash Growth	126.04%	-60.49%	-56.63%	-0.57%	-18.61%	28.17%
Net Cash Per Share	0.90	0.27	0.67	1.60	1.59	1.95
Filing Date Shares Outstanding	1,196	1,123	1,127	1,139	1,139	1,163
Total Common Shares Outstanding	1,196	1,123	1,127	1,139	1,145	1,163
Working Capital	2,595	1,277	3,767	4,870	4,799	5,323
Book Value Per Share	23.71	24.23	23.10	21.83	20.39	19.13
Tangible Book Value	27,897	26,776	25,669	24,500	23,024	21,938
Tangible Book Value Per Share	23.33	23.84	22.78	21.51	20.11	18.86
Buildings	2,243	2,202	2,138	2,039	1,991	1,908
Machinery	1,510	1,491	1,413	1,321	1,265	1,224
Construction In Progress	415.82	349.54	177.36	179.32	133	71.34

Source: S&P Capital IQ. Standard template. Financial Sources.